Archemix is a technology company.
Archemix has raised $102.0M across 2 funding rounds.
Archemix has raised $102.0M in total across 2 funding rounds.
Archemix has raised $102.0M in total across 2 funding rounds.
Archemix's investors include Atlas Venture, SV Health Investors.
Archemix was a biotechnology company that discovered, developed, and commercialized therapeutic aptamers—short, single-stranded DNA or RNA molecules designed to bind specific targets—for preventing and treating chronic and acute diseases, including cardiovascular, hematology, and oncology conditions.[1][2][3] Its key product candidates included ARC1779 for thrombotic microangiopathies and carotid endarterectomy procedures.[1] The company raised $116.5M in funding before reaching the asset sale stage, where its assets were purchased, marking the end of its independent operations.[1]
Archemix served patients and healthcare providers by addressing unmet needs in disease treatment through targeted aptamer therapies, offering potential advantages over traditional antibodies in specificity and manufacturability. However, no recent growth momentum is evident post-asset sale, positioning it as a historical player in biotech rather than an active startup.[1]
Founded in 2000, Archemix emerged during the early 2000s biotech boom, focusing on aptamer technology as a novel alternative to protein-based therapeutics.[1] Specific founders are not detailed in available records, but the company quickly advanced candidates like ARC1779 into development for surgical and vascular applications.[1] Early traction included securing $116.5M in funding, supporting pipeline expansion into oncology and hematology, though it ultimately culminated in an asset sale rather than IPO or sustained independence.[1]
Archemix stood out in the biotech landscape through:
Archemix rode the wave of nucleic acid-based therapeutics in the early 2000s, a trend predating modern mRNA and gene editing booms, by pioneering aptamers as precision medicine tools amid growing interest in non-protein biologics.[1][2][3] Timing aligned with advances in SELEX (Systematic Evolution of Ligands by EXponential enrichment) technology for aptamer discovery, capitalizing on market forces like rising chronic disease prevalence and demand for targeted therapies. Though its asset sale limited direct influence, Archemix contributed to the ecosystem by validating aptamers, influencing successors in oligonucleotide drugs and inspiring platforms from competitors like Molecular LogiX or CellCentric in cancer and protein engineering.[1]
Archemix's legacy endures through its acquired assets, likely integrated into larger pharma pipelines for aptamer-based drugs, rather than as a standalone entity. Emerging trends in next-generation biologics—such as RNA therapeutics and AI-driven drug design—could revive aptamer interest, potentially amplifying its technology's impact in oncology and cardiovascular markets. Its influence may evolve indirectly, shaping how biotech firms balance innovation with acquisition strategies in a consolidating industry. This positions Archemix as a foundational, if transitional, player in precision medicine's ongoing evolution.[1][2][3]
Archemix has raised $102.0M across 2 funding rounds. Most recently, it raised $50.0M Series B in April 2004.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2004 | $50.0M Series B | Atlas Venture | |
| Aug 1, 2002 | $52.0M Series A | Atlas Venture, SV Health Investors |